The aim of this study is to find out whether the combination of two approved drugs,
ipilimumab and nivolumab, in combination with cryoablation are safe and effective for
participants who have an unresectable melanoma that is resistant, or is growing, after
receiving immunotherapy with a PD-1 inhibitor.
The names of the study interventions involved in this study are:
- Cryoablation (an interventional radiology procedure that freezes part of a tumor)
- Ipilimumab (an immunotherapy)
- Nivolumab (an immunotherapy)